Regulating Blood Pressure During Recovery From Intracerebral Hemorrhage (REDUCE)
view all Clinical Trials
REDUCE is a pragmatic, randomized, open-label, blinded-endpoint trial comparing spironolactone-containing antihypertensive regimens versus standard antihypertensive regimens based on the 2017 AHA/ACC guidelines in ICH survivors. We will randomize a total of 200 patients, 100 of each white and non-white patients, at least 3 weeks after ICH to an antihypertensive regimen with spironolactone once daily or standard BP control based on the 2017 AHA/ACC guidelines for 1 year. Participants will undergo baseline testing for neurohormonal levels and will be followed for 12 months with regular assessment of home BP readings. The primary outcome of home systolic BP will be measured at 3 months.
For more information about this trial or to inquire about eligibility, call 215-707-7845 or email [email protected].